Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) was up 3.2% during trading on Wednesday . The stock traded as high as $3.02 and last traded at $2.94. Approximately 40,027 shares were traded during trading, a decline of 85% from the average daily volume of 261,100 shares. The stock had previously closed at $2.85.
Aadi Bioscience Price Performance
The company’s 50 day simple moving average is $2.68 and its 200 day simple moving average is $2.26. The company has a market capitalization of $72.61 million, a PE ratio of -1.29 and a beta of 0.68.
About Aadi Bioscience
Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.
The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).
See Also
- Five stocks we like better than Aadi Bioscience
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
